| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | 0.31 | 7e-05 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.24 | 7e-05 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.16 | 0.0002 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0002 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.15 | 0.0002 |
| mRNA | A-770041 | GDSC1000 | pan-cancer | AAC | 0.22 | 0.0003 |
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | -0.22 | 0.0004 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0005 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | 0.25 | 0.0006 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0009 |